Interpace Biosciences Q3 revenue down

Interpace Biosciences

12/11/2025 21:12

Overview

Interpace Q3 revenue falls 29% yr/yr, but rises 22% from pro forma results

Company reports record thyroid test volumes and cash collections in Q3

Interpace focuses on lab efficiency and AI, supporting strategic investments

Outlook

Company did not provide specific future guidance in press release

Result Drivers

RECORD THYROID TEST VOLUME - Co achieved record thyroid test volumes, driven by higher testing activity and improved reimbursement strategies

LAB EFFICIENCY INVESTMENTS - Strategic investments in AI and automation improved lab operational efficiency and strengthened balance sheet

THYROID-ONLY FOCUS - Transition to thyroid-only diagnostics business contributed to revenue growth compared to pro forma results

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
$8.76 mln
Q3 Net Income
$911,000
Q3 Gross Profit
$5.44 mln
Q3 Operating Expenses
$4.29 mln
Q3 Operating Income
$1.15 mln


Press Release: ID:nGNX8GNC6P

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)